Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia. (March 2018)

• Record Type: Journal Article
• Authors: Umerez, Maitane; Garcia-Obregon, Susana; Martin-Guerrero, Idoia; Astigarraga, Itziar; Gutierrez-Camino, Angela; Garcia-Orad, Africa
• Is Part Of: Pharmacogenomics. Volume 19:Number 4(2018)
• Page Start: 361
• Page End: 373
• Publication Date: 2018-03
• Subjects: microRNA -- pediatric ALL -- pharmacoegipenetics -- resistance -- SNP -- toxicity; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2017-0164
• Languages: English
• ISSNs: 1462-2416

Abstract

Childhood acute lymphoblastic leukemia survival rates have increased remarkably during last decades due, in part, to intensive treatment protocols. However, therapy resistance and toxicity are still two important barriers to survival. In this context, pharmacoepigenetics arises as a tool to identify new predictive markers, required to guide clinicians on risk stratification and dose individualization. The present study reviews current evidence about miRNA implication on childhood acute lymphoblastic leukemia therapy resistance and toxicity. A total of 12 studies analyzing differential miRNA expression in relation to drug resistance and six studies exploring the association between miRNAs-related SNPs and drug-induced toxicities were identified. We pointed out to miR-125b together with miR-99a and/or miR-100 overexpression as markers of vincristine resistance and rs2114358 in mir-1206 as mucositis marker as the most promising results.